[Determination of 5-hydroxytryptamine,Adrenalin and Noradrenalin in Human Plasma by Pre-column Derivatization HPLC-MS/MS].

OBJECTIVE: To establish a method for the determination of 5-hydroxy tryptamine (5-HT),adrenalin (AD) and noradrenalin (NA) in human plasma using pre-column derivatization HPLC-MS/MS. Methods Derivatives of the plasma samples were produced with dansyl chloride under pH 10.5,and then extracted and enriched with ethyl acetate. The detected chemicals were separated using Ultimate C18 (50 mm×4.6 mm,5 µm) with acetonitrile-water-formic acid=95∶5∶0.05 (V∶V∶V) at 0.2 mL/min. The HPLC-MS//MS system was operated under a multiple reaction monitoring mode (MRM) using the electrospray ionization technique in positive mode. RESULTS: Linear range of the calibration curve appeared in 250-2.5 ng/mL. The method had a less than 9% intra- and inter-assay relative standard deviation (RSD),95.44%-109.71% recoveries,and 4.86%-12.81% matrix effects. CONCLUSION: This method is simple,accurate,and suitable for detection of 5-HT,AD and NA in human plasma.

[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction].

OBJECTIVE: To compared the differences in pharmacokinetics of phosphate retagliptin tablets in patients with varying degrees of renal dysfunction. METHODS: A total of 32 patients were categorized into five groups according to their renal function: normal,mild dysfunction, moderate dysfunction,severe dysfunction,and end stage renal dysfunction (ESRD). All of the patients took a single dose of 50 mg phosphate retagliptin tablet. Their plasma and urinary concentrations of phosphate retagliptin (SP2086) and phosphate retagliptin acid (SP2086 acid) were determined using LC-MS/MS methods. The plasma pharmacokinetic parameters were calculated using WinNolin 6.1 software. RESULTS: Peak concentrations (Cmax) of SP2086 reached at (1.07±0.35) h in the patients with mild renal dysfunction,(1.50±0.89) h in the patients with moderate renal dysfunction,(1.67±2.16) h in the patients with severe renal dysfunction,(2.42±2.15) h in the patients with ESRD,and (1.75±1.21) h in the normal participants,with a clearance (CL/F) of (23.50±6.01) ,(12.90±4.34) ,(6.70±1.55) ,(3.10±0.48) ,and (30.50±10.70) L/h,respectively. With the increasing damages in renal function presented an incease in Cmax,time to reach Cmax (Tmax),and area under curve (AUC), a decrease in CL/F, of SP2086 and SP2086 acid. The 0-96 hurine cumulative excretion percentage (Ae%) of SP2086 ranged from 0.441% to 4.530%. The Ae% of SP2086 acid reached (71.7±14.3) % in the patients with mild renal dysfunction, (59.5±22.7) % in the patients with moderate renal dysfunction, (63.3±13.9) % in the patients with severe renal dysfunction, (34.1±20.0) % in the patient with ESRD,and (74.2±14.6) % in the normal participants, with a renal clearance (CL/R) of (220.0±51.2),(105.0±64.5),(54.5±7.6),(13.5±7.8),and (289.0±73.7) mL/min,respectively. Compared with the participants with normal renal function,the AUCs of SP2086 and SP2086 acid were 1.44 times and 2.32 times higher in the patients with moderate renal dysfunction,2.20 times and 4.39 times higher in the patients with severe renal dysfunction, and 2.83 times and 9.28 times higher in the patients with ESRD. CONCLUSION: The dosage of phosphate retagliptin tablet is recommended at 100 mg/d for patients with normal renal function and those with mild renal dysfunction,at 50 mg/d for patients with moderate renal dysfunction,and at 25 mg/d for patients with severe renal dysfunction. No phosphate retagliptin tablet is recommended for patients with ESRD.

[Determination of Voriconazole in Human Plasma and Its Bioequivalence by HPLC-MS/MS].

OBJECTIVE: To develop a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for the determination of voriconazole in human plasma and its bioequivalence. METHODS: 48 healthy male volunteers received a single dose of 200 mg voriconazole tablets in a two period (with two preparations) and randomized crossover bioequivalence study. Their plasma voriconazole was determined using HPLC-MS/MS. The pharmacokinetic parameters and bioequivalence of the two preparations were calculated with WinNonlin®6.1. RESULTS: The calibration curve of voriconazole ranged from 1 to 5 000 ng/mL. The HPLC-MS/MS method had less than 11% intra- and inter-day relative standard deviation (RSD),with 100.00% to 109.73% accuracies. The RSD of the matrix effect of voriconazole adjusted with internal standard was less than 15%. The extract recoveries exceeded 50% with good stability. The 90% confidence intervals for the peak concentration (Cmax) and the area under the curve (AUC0-t and AUC0-∞)of voriconazole fell into the bioequivalence range of 80.00%-125.00%. There was no significant difference in peak time (Tmax) between the two preparations. CONCLUSION: HPLC-MS/MS can be used for determination of voriconazole in human plasma. The two tested preparations of voriconazole are bioequivalent.

[LC-MS/MS Determination of Tenofovir in Human Plasma and Its Bioequivalence].

OBJECTIVE: To develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for detecting tenofovir in human plasma. METHODS: Twenty four healthy male volunteers received a single oral dose of 300 mg tenofovir disoproxil fumarate tablets under fasting and high-fat diet conditions in a randomized four-way crossover bioequivalence study with two preparations of tablets. Plasma samples were taken and analyzed using the LC-MS/MS method. The pharmacokinetic parameters of the two preparations were calculated and compared statistically to evaluate their bioequivalence using Phoenix Winnonlin6.3. RESULTS: Linear detection responses were obtained for tenofovir at the range from 3.13 to 500 ng/mL. The intra- and inter-day precisions were high,with lower than 5.43% [relative standard deviation (RSD)%],high recovery and good stability. The 90% confidence intervals of peak concentration (Cmax) of tenofovir and its area under the curve (AUC0-t and AUC0-∞ ) all fell within the bioequivalence limit 80.00%-125.00% under both fasting and high-fat diet conditions. No significant difference in peak time (Tmax) was demonstrated between the two preparations (P>0.05) . CONCLUSION: The LC-MS/MS method can be used for simultaneous determination of tenofovir in human plasma. The two preparations of tablets are bioequivalent.

[Pharmacokinetics Study of Phentolamine Mesylate Injection in Healthy Volunteers].

OBJECTIVE: To study the pharmacokinetic profile of phentolamine mesylate injection in healthy Chinese volunteers. METHODS: A total of 16 healthy volunteers were randomly divided into two groups, each receiving anterior teeth submucosal infiltration anesthesia and inferior alveolar nerve block anesthesia, respectively. The participants were injected with 0.9 mL, 1.8 mL, and 3.6 mL of 2% lidocaine HCl with 1∶100 000 epinephrine over three periods sequentially, followed by corresponding sequential injection of 0.2 mg, 0.4 mg, 0.8 mg of phentolamine mesylate at the same sites 30 min later.Blood samples were drawn from 5 min before injection to 15 h post the injection of phentolamine mesylate (16 time points). Adverse events were closely observed all the time. Plasma phentolamine mesylate was detected using UPLC-MS/MS with isotope as internal standard. WinNolin 6.1 software was used to calculate the pharmacokinetic parameters. RESULTS: Time to peak concerntration (Tmax) ranged from 12 to 13 min. Half-time of elimination (t1/2) ranged from 3.84 to 4.07 h, with a clearance (CL) of 190 L/h. Peak concentration (Cmax), area under concentration-time curves from 0 to t hour and from 0 to infinite time (AUC0-t and AUC0-∞) increased proportionally in the dose range of 0.2 mg to 0.8 mg. The results of confidence interval analysis showed nearly linear dynamic characteristics for the injection of phentolamine mesylate. All participants experienced mild adverse events, including pain at the injection point, dizziness, and palpitations. These adverse events disappeared without treatments. CONCLUSIONS: Phentolamine mesylate injection is effective for reversing oral local anesthetic effects.

Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO-R Agonist, in Healthy Individuals.

Hetrombopag olamine (hetrombopag) is a novel small-molecule, orally bioavailable, non-peptide thrombopoietin (TPO) receptor agonist that is being developed as the treatment for thrombocytopenia. Two randomized, placebo-controlled phase I studies were conducted in 72 healthy individuals to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of hetrombopag. Hetrombopag was orally administered with a single dose in five dose cohorts (5 mg, 10 mg, 20 mg, 30 mg or 40 mg) in the first study, and given once daily for 10 days in three dose cohorts (2.5 mg, 5.0 mg or 7.5 mg) in the second study, respectively. Hetrombopag was well tolerated, and the majority of adverse events associated with medicine were platelet elevations significantly above the normal range in healthy individuals. The single dose-escalation study revealed a Tmax of approximate 8 hr, and a t1/2 of 11.9 hr to 40.1 hr in a dose-prolonged manner. A dose-proportional increase in maximum concentration (Cmax ) of hetrombopag was observed, with area under the curve (AUC) increasing in a greater than dose-proportional manner. The plasma concentration of hetrombopag reached the steady-state after 7 days. The steady-state AUC0-24 hr and Cmax were dose-proportionally elevated from the 5.0 mg to 7.5 mg dose level. The potent pharmacological effect of the hetrombopag-induced platelet elevation was observed in a time- and dose-dependent manner. Furthermore, the thrombopoietic response was significantly (p < 0.0001) correlated to the plasma exposure level of hetrombopag in single and multiple administration studies. Taken together, results of this study support further clinical development of hetrombopag in patients with thrombocytopenia.

[Determination of Warfarin Enantiomers in Human Plasma with HPLC-MS/MS].

OBJECTIVE: To establish a high performance liquid chromatography-mass spectrometry/mass spectrometry (HPLC-MS/MS) method for determination of warfarin enantiomers in human plasma. METHODS: Warfarin enantiomers were extracted with ethyl acetate. The HPLC-MS/MS method used naproxen as internal standard, with methanol : water : formic acid = 85 : 15 : 0.05 as mobile phase, at a flow rate of 0.18 mL/min. R-warfain, S-warfarin and internal standard (IS) were separated on column MS Chiral MS-OD (50 x 2.1 mm, 3 µm). Warfarin enantiomers were protonated with electroapry ionization (ESI) in negative electron ionization mode. The ion pairs being detected were (m/z) 307.2-160.9 (R-warfain and S-warafrin) and (m/z) 228.9 --> 185.1 (IS). RESULTS: The within-run precision relative standard deviations (RSD) and between-run precision RSD of R-warfarin were 3.2%-5.8% and 2.5%-5.1%, respectively. The method recoveries and extraction recoveries of R-warfarin were (96.1 ± 5. 6)%-(105.4 ± 4.7)% and 80.7%-84.4%, respectively. The matrix effect RSD was less than 10%. The within-run precision RSD and between-run precision RSD of S-warfarin were 3.7%-5.2% and 3.2%-4.8%, respectively. The method recoveries and extraction recoveries of 5-warfarin were (98.3 ± 5.1)%-(103.7 ± 3.8)% and 81.3%-84.6%, respectively. The limit of quantification was 0.1 µg/mL for both analytes. CONCLUSION: This new method is fully validated with satisfactory accuracy and adequate reproducibility. Therefore, it can be applied for separating and detecting plasma warfarin enantiomers.

[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS].

OBJECTIVE: To develop a sensitive and reproducible HPLC-MS/MS method for analyzing dimemorfan in human plasma and urine. METHODS: Dimemorfan was extracted from plasma and urine by redistilled ether, with lidocaine serving as the internal standard (IS). The analysis was performed on a column of ultimate C18 (50 mm x 4.6 mm, 5 microm) with the mobile phase consisting of methyl alcohol-water-formic acid = 75:25 : 0.05 at a flow rate of 0. 2 mL/min. Dimemorfan was detected by API 3000 mass spectrometer, with multiple reaction monitoring after protonated with ESI in positive electron ionization mode. The ion pairs being detected were (m/z) 256.4-->155. 3 (dimemorfan) and 235.4-->86.1 (lidocaine), respectively. RESULTS: The regression equation for dimemorfan showed excellent linearity (r = 0.995 7) from 0. 025 to 5.0 ng/mL of plasma with detecting limitation of 0.025 ng/mL and perfect linearity (r = 0.9983) from 0.1 to 20.0 ng/mL of urine with detecting limitation of 0.1 ng/mL. The method recoveries of dimemorfan in plasma and urine were ranging from 103.38% to 106.88% and 90.05% to 101.40%, respectively. The maximum intra-day and inter-day relative standard deviations (RSD) of concentration of dimemorfan were 5.92% and 5. 70% (for plasma), 10.35% and 8.80% (for urine), respectively. CONCLUSION: This new method was validated to be accurate and sensitive to determinate the concentration of dimemorfan in plasma and urine samples, and can be applied for pharmacokinetic studies of dimemorfan.

Pharmacokinetic and pharmacodynamic comparison of chinese herbal ointment liu-he-dan and micron liu-he-dan ointment in rats with acute pancreatitis.

Aim. To compare the pharmacokinetics and pharmacodynamics of herbal ointment Liu-He-Dan (LHD) and micron LHD (MLHD) in rats with acute pancreatitis (AP). Methods. Twenty rats were allocated into normal, AP, LHD, and MLHD groups. LHD or MLHD was applied on rats' abdomens. Plasma levels of emodin, rhein, aloe emodin, physcion, and chrysophanol were determined by high performance liquid chromatography-mass spectrometry-mass spectrometry (HPLC-MS-MS) at different time points, and the pharmacokinetic parameters were calculated. Serum amylase, TNF- α , IL-6, and IL-10 levels, and the pancreatic pathological scores were determined at 48 h after LHD or MLHD treatment. Results. T 1/2 α and area under the curve (AUC) of emodin in the MLHD group were lower than those in the LHD group, while T 1/2 α and AUC of aloe emodin in the MLHD group were higher than those in the LHD group (P < 0.05). T 1/2 α and T max of physcion in the MLHD group were significantly shorter than those in the LHD group (P < 0.05). Compared with the AP group, the amylase, malondialdehyde (MDA), TNF- α , and IL-6 levels decreased significantly after three days of treatment in LHD and MLHD groups, while the levels of superoxide dismutase (SOD), TNF- α , and the pancreatic pathological score, were similar. The pharmacodynamic parameters between the LHD and MLHD groups were similar. Conclusion. MLHD had better pharmacokinetics than, and similar pharmacodynamics to, LHD in the management of rats with AP, which indicated that MLHD might be substituted for LHD in the treatment of AP and thus reduce the amount of medicinal herbs used.

[Association of CYP3A5 and MDR1 genetic polymorphisms with the blood concentration of tacrolimus in Chinese liver and renal transplant recipients].

OBJECTIVE: To investigate the association of CYP3A5 and MDR1 genetic polymorphisms with the concentration/ dose (C/D) ratio of tacrolimus for the feasibility of individualized medication. METHODS: The concentration of tacrolimus was detected by enzyme-multiplied immunoassay technique, and was adjusted by weight and dosage to C/D ratios. The single nucleotide polymorphisms of CYP3A5 A6986G and MDR1 C3435T, G2677T/ A, T1236C were determined by TaqMan RT-PCR. The differences of C/D ratio were compared among all of the genotype groups. RESULTS: There were 5 cases with CYP3A5 *1/*1, 22 cases with CYP3A5 *1/*3, and 33 cases with CYP3A5 *3/*3. The C/D ratios of the patients with at least one CYP3A5 *1 allele (130.40 +/- 53.94) was significantly lower than those with CYP3A5 *3/*3 (198.12 +/- 90.80) (P < 0.01). For MDR1, there were 22, 23 and 15 recipients carried C/C, C/T and T/T respectively in C3435T, and 8, 32 and 20 recipients carried T/T, T/ C and C/C respectively in T1236C. The carriers with G/G, G/T, G/A, T/A, T/T were 9, 24, 5, 8 and 14 respectively in G2677T/A. No significant difference was found in the C/D ratios of tacrolimus among different MDR1 genotypes. CONCLUSIONS: Determination of CYP3A5 genotype could help individualize tacrolimus dose regimen prospectively. The patients with CYP3A5 *3 *3 require less dose of tacrolimus to reach the same concentrations comparing with the patients with at least one CYP3A5 * 1 allele.

[Pharmacokinetics study of amoxicillin sodium clavulanate potassium (10:1) injection in healthy volunteers].

OBJECTIVE: To study the pharmacokinetics of amoxicillin sodium clavulanate potassium (10:1) injection with different single doses intravenous infusion and one dose repeated intravenous injection in healthy volunteers for guiding the rational clinical regimen. METHODS: Using infusion pump constantly intravenous dripping in 30 min, 4 mL blood samples were collected before and after the administration at 10 min, 20 min, 30 min, 45 min, and 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10 h. The plasma concentrations of amoxicillin and clavulanate were detected by high performance liquid chromatography- mass spectrometry/mass spectrometry method. The pharmacokinetic parameters were calculated by DAS2.0.1 software. RESULTS: The dispositions of amoxicillin and clavulanate matched three or two compartment model with the weight coefficient 1/cc. To avoid the biases caused by compartment model fitting, the pharmacokinetic parameters were statistical moment parameters of non-compartment model. The peak concentrations, the areas under curve, the half-lifes and the clearances after single injections of 0. 55 g, 1.1 g and 2.2 g indicated that both amoxillin and clavulanate had linear dynamics characteristics. After 1.1 g single dose and multiple doses infusion, the pharmacokinetic parameters of amoxicillin and clavulanate were close respectively, and the trough concentrations before the 7th to 13th administration were lower than the detection limitation, which implied that the previous administration had cleared out before the next administration, and no accumulation happened after multiple doses. CONCLUSIONS: The amoxicillin sodium clavulanate potassium (10:1) injection possesses the linear kinetics. The dosage regimen of 1.1 g Q8h intravenous infusion could meet the needs of clinical therapy.

[Pharmacokinetics of injected cefozopran hydrochloride in healthy volunteers].

OBJECTIVE: To study the pharmacokinetics of injected cefozopran hydrochloride in healthy volunteers. METHODS: 24 healthy volunteers were enrolled to receive low (0.5 g), middle (1.0 g), high (2.0 g) doses of single injection and multiple doses (1.0 g) injection of cefozopran hydrochloride in an open randomized study. The plasma concentrations of cefozopran were determined by RP-HPLC. The DAS2.0 was used to fit the concentration-time data and to calculate the pharmacokinetic parameters. RESULTS: The main pharmaeokinetic parameters for a single injection of low, middle and high doses of cefozopran were as follows: Cmax (48.27 +/- 9.84), (77.99 +/- 15.08) and (171.59 +/- 18.27) mg/L; Tmax (0.50 +/- 0.00), (0.51 +/- 0.02) and (0.51 + 0.02) h; AUCo-t (92.43 +/- 24.02), (152.45 +/- 16.26) and (341.03 +/- 44.16) mg x h/L; t1/2beta (1.97 +/- 0.19), (2.44 +/- 0.24) and (2.18 +/- 0.31) h, respectively. The main pharmacokinetic parameters for a multiple doses injection of cefozopran were as follows: Cmax (80.39 +/- 11.86) mg/L; Tmax (0.51 +/- 0.02) h; AUCo-t (159.74 +/- 15.06) mg x h/L; t1/2beta (2.55 +/- 0.55) h. The accumulative rate of cefozopran through urine pathway within 24 h was (89.4 +/- 15.5)%. The statistical analysis showed that Cmax, AUCo-t, and AUCo-infinity increased significantly with increased doses of injection (P < 0.05). Those parameters were linearly correlated with the doses of injection (r = 0.9950, 0.9960, 0.9963). However, dosage did not have an impact on other pharmacokinetic parameters (P > 0.05). No gender differences in the parameters were found (P > 0.05). CONCLUSION: Cefozopran hydrochloride performs a linear kinetics in healthy volunteers. The main pharmacokinetic parameters have no significant gender differences, and there is no drug accumulated with multiple doses of injection.

[Determination of probucol in human plasma by HPLC-MS/MS].

OBJECTIVE: To develop a specific and sensitive method for the determination of probucol in human plasma using HPLC-MS/MS technique. METHODS: Probucol were extracted from plasma by ethyl ether: dichloromethane (1:1, V/V), with physcion as an internal standard. The analytes went through the column of ultimate CN (50 mm x 4.6 mm, 5 microm) with mobile phase acetonitrile: water: ammonia water = 97:3:0.05 (adjusted pH = 7.2 with formic acid). Probucol was analyzed with a negative mode. The ion pairs being detected were 515.5-->236.1 (probucol) and 283.0-->239.9 physcion, respectively. RESULTS: The established method was able to determine probucol in human plasma over the range of 2.5-6000 ng/mL, with a method recovery ranging from 93.02% to 104.12%. The intra and inter day variances were below 4.67% and 5.72%. CONCLUSION: The HPLC-MS/MS method for analyzing probucol was validated. It is sensitive and suitable for pharmacokinetic studies of probucol.

[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS].

OBJECTIVE: To develop and validate a normal phase HPLC-MS/MS method for the determination of donepezil enantiomer in human plasma. METHODS: Donepezil was extracted from plasma by n-hexane:isopropanol (98:2, V/V) with lidocaine serving as an internal standard. The analytes went through the column of CHIRALCEL OJ-H (250 mm x 4.6 mm, 5 microm) with mobile phase n-hexane:n-propanol:diethylamine (60:40: 0.1, V/V/V). Donepezil enantiomer was determined by API 3000 in MRM mode. RESULTS: The retention time of S-DN and R-DN were 15.56 min and 18.41 min, respectively. The calibration curves were linear in a range from 0.051 to 7.596 ng/mL for S-DN, and from 0.049 to 7.404 ng/mL for R-DN, respectively, both with more than 0.99 correlation coefficients. The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively. CONCLUSION: This normal phase HPLC-MS/MS method is simple, rapid, sensitive and accurate for the determination of donepezil enantiomer in human plasma and is suitable for pharmacokinetic studies of donepezil enantiomers.

[Determination of ubenimex in human plasma by HPLC-MS/MS].

OBJECTIVE: To establish a liquid chromatography tandem mass spectrometry method for the determination of ubenimex in human plasma. METHODS: The essay was conducted with an API 3000 HPLC-MS/MS system consisted of a Ultimate C18 column (50 mm x 4.6 mm, 5 microm). The mobile phase consisted of methanol-water-formic acid (70 : 30 : 0.05, V/V/V) at a flow rate of 0.2 mL/min. Granisetron was used as the internal standard. The sample was extracted by solid phase extraction column and was operated under the multiple reaction monitoring mode using the electrospray ionization technique in positive mode. RESULTS: The linear range of ubenimex was 0.4-4000 ng/mL. The limit of quantity was set at 0.4 ng/mL. The within-day and between-day variations were less than 6%. CONCLUSION: This method for the quantitative determination of ubenimex was proved to be accurate, sensitive, selective and convenient and can be applied in the determination of ubenimex in human plasma.

[Determination of biapenem in human plasma by high performance liquid chromatography].

OBJECTIVE: To establish a method to determine biapenem in human plasma with high performance liquid chromatography. METHODS: Chromatographic separation was performed on a YMC-C18 column (150 mmX 4. 6 mm, 5 microm) eluted with a mobile phase comprising 98 : 2 (V = V) of sodium acetate (0.1 mol/L, adjust with acetic acid to pH 4.5) and acetonitrile with a flow rate of 1.0 mL/min. The detection wavelength was set at 300 nm. Temperature was controlled at 35 degrees C. The plasma samples were precipitated with acetonitrile. The supernatant was vortexed with dichloromethane and 0.03 mL of the aqueous layer was injected for analysis. RESULTS: The method was valid to detect biapenem in a range of 0.0625 mg/L to 80 mg/L (correlation coefficient 0.999). The pretreatment recovery of biapenem ranged from 96.11% to 98.76%. The methodological recovery of biapenem ranged from 99.14% to 109.69%. The inter-day RSD ranged from 0.92% to 2.79%. The intra-day RSD ranged from 2.46% to 4.08%. Less than 7% change of results was observed after the sample was stored in room temperature for 5 h, frozen and defrozen 3 times, stored at -30 degrees C for 28 d, stayed in autosampler for 24 h, and injected twice. CONCLUSION: The method is sensitive, accurate and easy to perform, which offers a satisfactory tool for the determination and pharmacokinetic study of biapenem.

[Determination of lidocaine and its metabolites in human plasma by liquid chromatography in combination with tandem mass spectrometry].

OBJECTIVE: To establish a liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method for the determination of lidocaine (LDC) and its metabolites, monoethylglycinexylidide (MEGX) and glycinexylidide (GX), in human plasma. METHODS; The assay was conducted with an API 3000 HPLC-MS/MS system consisted of a Ultimate C18 column (50 x 4.6 mm, 5 microm). The mobile phase consisted of methanol: 5 mmol/ L ammonium acetate (50:50, pH was adjusted to 5.0 by formic acid) and the flow rate was set at 0.2 mL/min. The alkalinized sample was extracted with ethyl acetate. After evaporation of the organic layer, the residue was dissolved in mobile phase and the drug was determined by HPLC-MS/MS using electrospray ionization. RESULTS: The calibration curve was linear in a range from 15.625 to 2000 ng/mL for LDC. Linear calibration curves were obtained in the range of 1.5625 to 200 ng/mL for both for MEGX and GX. The limit of quantification for LDC, MEGX and GX was set at 15.625, 1.5625 and 1.5625 ng/mL. CONCLUSION: This method for the quantitative determination of lidocaine and its metabolites in human plasma is simple, rapid, sensitive and accurate. Therefore it can be used for the determination of lidocaine and its metabolites in clinical practice.

[Detecting penehyclidine hydrochloride in rats plasma and tissues with HPLC-MS/MS].

OBJECTIVE: To develop a method for detecting penehyclidine hydrochloride (PH) in mouse plasma and tissues using HPLC-MS/MS. METHODS: The plasma and tissue samples were extracted with petroleum ether, ethyl ether (70:30). The isolation of PH was achieved on an Allure C18, (50 x 2.1 mm, 5 microm) column, with methanol/5 mmol/L ammonium acetate/triethylamine = 90/10/0.05 (adjusted pH 5.8 by formic acid as mobile phase. Benzhydramine was used as the internal standard. RESULTS: The calibration curves were linear over the range of 0.39-200 ng/mL for plasma and 0.391-100 ng/mL for tissues. The extraction recovered 67.32-70.80% of PH in plasma, 84.99%-89.27% of PH in lung tissues, and 76.86%-81.98% of PH in brain tissues. The HPLC detected 97.66%-99.97% of PH in extracted samples of plasma, 96.55%-101.65% extracted samples of lung and 95.18%-100.21% of extracted samples of brain. The within-day RSD were 1.94%-2.93%, 1.73%-3.70% and 2.35%-2.79% for plasma, lung, and brain, respectively. The between-day RSD were 3.00%-3.85% 2.86%-3.94% and 2.77%-5.00% for plasma, lung, and brain, respectively. Both the long-term and freeze-thaw stabilities were acceptable. The long-term RSD were 1.52%-5.26%, 1.88%-2.93%, and 2.22%-3.76% for plasma, lung, and brain, respectively. The freeze-thaw RSD were 0.38%-3.55%, 2.79%-9.60%, and 1.35%-2.29% for plasma, lung, and brain, respectively. CONCLUSION: The assay is simple and accurate, with good reproducibility, and can satisfy to the needs of pharmacokinetics and relative bioavailability studies on penehyclidine hydrochloride.

[Determination of nicacid and its metabolites in human plasma by HPLC-MS/MS].

OBJECTIVE: To develop a sensitive HPLC-MS/MS method for the determination of nicacid and its metabolites in human plasma. METHODS: The assay was conducted with an API 3000 LC-MS/MS system comprising of a Genimi C18 column (50 x 3.00 mm, 3 microm), and an eluate of 0.1% acetic acid-methanol-isopropyl alcohol (98: 1:1), and flow rate was 0.2 mL/min. Acetonitrile was used to precipitate protein from the plasma samples. The loading samples contained the residue from the supernatant that were dissolved in the eluate solution and rinsed by dichloromethane was used as the loading samples. The ion pairs of m/z 124.1-->80.0, m/z 123.1-->80.0, m/z 181.1-->135.0 and m/z 138.1-->92.0 were used to quantify nicacid, niacinamide, nicotinuric acid and 6-methyl nicotinic acid (IS), respectively. RESULTS: The standard curves of nicacid, niacinamide and nicotinuric were linear in the range of 1.25-320 microg/L, 1.25-1280 microg/L and 1.25-1280 microg/L, respectivly. All with a low determination limits of 1.25 microg/L and a less than 9% within-day and inter-day RSD. The recovery rates reached 89% to 105%. CONCLUSION: The method is simple, rapid, sensitive, and suitable for the determination of nicacid and its metabolites in human plasma.

Effect of severe acute pancreatitis on pharmacokinetics of Da-Cheng-Qi Decoction components.

AIM: To investigate the effect of severe acute pancreatitis (SAP) on pharmacokinetics of Da-Cheng-Qi Decoction (DCQD) components in rats. METHODS: Rats were divided into SAP group and sham-operation group as a control group (n = 6). Rhein, chrysophanol, rheochrysidin, magnolol, hesperidin and naringin in DCQD were quantified in rat serum by high performance liquid chromatography tandem mass spectrometry for studying their pharmacokinetics. RESULTS: Early absorption of each DCQD component was tended to degrade in SAP group after treatment with DCQD by gavage. The C(max) (chrysophanol, P = 0.0059; rheochrysidin, P = 0.0288; magnolol, P = 0.0487; hesperidin, P = 0.0277; naringin, P = 0.0023) and AUC (rhein, P = 0.0186; chrysophanol, P = 0.0013; magnolol, P = 0.001; hesperidin, P = 0.0081; naringin, P = 0.0272) of DCQD component were obviously lower in SAP group than in control group. The T(1/2alpha) of chrysophanol and rheochrysidin (P = 0.0467 and 0.0005, respectively) and T(max) of chrysophanol and rheochrysidin (P = 0.0101 and 0.0037, respectively) lasted longer in SAP group than in control group. CONCLUSION: SAP can significantly impact the absorption of DCQD components in rats and their pharmacokinetic parameters.